Please login to the form below
tucatinib
This page shows the latest tucatinib news and features for those working in and with pharma, biotech and healthcare.
UK approval for Seagen’s oral HER2 inhibitor Tukysa
The MHRA has cleared Tukysa (tucatinib) as an add-on therapy to Roche’s anti-HER2 antibody Herceptin (trastuzumb) plus Xeloda (capecitabine) for adults patients with HER2-positive locally-advanced or
Latest news
-
Merck signs separate agreements with Seattle Genetics for two cancer drugs
In a separate agreement, Seattle Genetics has granted Merck an exclusive license to commercialise Tukysa (tucatinib), a small molecule tyrosine kinase inhibitor, in Asia, the Middle East, Latin America and other
-
Seattle Genetics wins FDA priority review for oral HER2 drug
Seattle is seeking approval for tucatinib in combination with Roche’s anti-HER2 antibody (trastuzumab) plus Xeloda (capecitabine). ... If Seattle does gain approval for tucatinib, it will go on to compete with rival HER2 inhibitor Enhertu, marketed by
-
AZ, Daiichi Sankyo get early okay for DS-8201, now named Enhertu
In the meantime, further HER2 competition could be coming from Seattle Genetics’ oral drug tucatinib, which recently cleared the phase 3 HER2CLIMB trial as an add-on to Herceptin plus
-
EMA backs adjuvant use of Roche’s breast cancer ADC Kadcyla
Also on the horizon is Seattle Genetics’ oral HER2 drug tucatinib, which recently cleared the phase 3 HER2CLIMB trial as an add-on to Herceptin plus Roche’s chemotherapy Xeloda (capecitabine) ... HER2CLIMB-02 will compare tucatinib to placebo in
-
AZ, Daiichi Sankyo strengthen case for HER2 candidate
Also looking to encroach on the HER2 market is Seattle Genetics, with its orally-active HER2 inhibitor tucatinib.
Merck signs separate agreements with Seattle Genetics for two cancer drugs
Seattle Genetics wins FDA priority review for oral HER2 drug
AZ, Daiichi Sankyo get early okay for DS-8201, now named Enhertu
EMA backs adjuvant use of Roche’s breast cancer ADC Kadcyla
More from news
Approximately 2 fully matching, plus 5 partially matching documents found.
Latest Intelligence
-
Deal Watch January 2018
Acquisition company. 628. Cascadian Therapeutics/Seattle Genetics. Lead programme tucatinib, oral, small molecule TKI highly selective for HER2 (p2). ... Undeterred Seattle Genetics went on to buy Cascadian Therapeutics at the very end of January for
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
-
Senior Account Manager
-
Competitive salary offered
-
Omnichannel Strategy Consultant
-
Competitive Salary
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- US demand for COVID-19 antibody treatments rising fast
- Data shows patients treated with Biogen's MS therapies mount an effective antibody response to COVID-19 vaccination
- EU “still interested” in Valneva COVID vaccine despite UK snub
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Sandoz completes acquisition of GSK’s cephalosporin business
- Biosimilars boosted by FDA's landmark ruling for Boehringer’s Cyltezo
- Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes
- Best practice in UK diabetes care recognised at prestigious national awards
- Live Webinar: Accelerating Revenue Cycle Performance in the Healthcare Industry
- The FDA vaccine advisory board recommends booster shots of both the J&J and Moderna vaccines
- Biogen's ALS drug tofersen misses phase 3 endpoint
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- US demand for COVID-19 antibody treatments rising fast
- Results of AstraZeneca’s TACKLE phase 3 trial show antibody combination reduces risk of severe COVID-19 or death
- David Hunt launches independent agency The Considered
- Live Webinar: Accelerating Revenue Cycle Performance in the Healthcare Industry
PMHub
3 Monkeys Zeno
3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...
Latest intelligence
- Breaking the silence: It’s time to talk about the menopause
- Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
- Committing time to making meaningful connections - top 5 tips
- Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
- News:
- Senior Analytics Specialist joins Research Partnership...
